Telday-40/Telday-80

Telmisartan

Monotherapy or in combination w/ other antihypertensive agents for the treatment of HTN.

HTN Initially 40 mg once daily. Mild to moderate hepatic impairment Max: 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Patients w/ biliary obstructive disorder & severe hepatic impairment. Do not co-administer w/ aliskiren in patients w/ diabetes. Pregnancy (2nd & 3rd trimester) & lactation.

Symptomatic hypotension in vol- or salt-depleted patients (eg, those being treated w/ high doses of diuretics). Hyperkalemia may occur particularly in patients w/ advanced renal impairment, heart failure, on renal replacement therapy, on K supplements, K-sparing diuretics, K-containing salt substitutes or other drugs that increase K levels. Patients w/ biliary obstructive disorders or hepatic insufficiency, severe CHF or renal dysfunction, unilateral or bilateral renal artery stenosis. Avoid combined use of renin-angiotensin aldosterone system inhibitors. Concomitant use w/ ramipril. Monitor BP, renal function & electrolytes. Do not co-administer w/ aliskiren in patients w/ diabetes; avoid use w/ aliskiren in patients w/ renal impairment (GFR <60 mL/min/1.73m²). Not recommended in patients w/ primary aldosteronism. Patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy. Consider periodic determinations of serum electrolytes to detect possible electrolyte imbalances. Can cause fetal & neonatal morbidity & death during pregnancy. Neonates.

Renal dysfunction upon use w/ ramipril. Headache, dizziness, asthenia, coughing, nausea, fatigue, weakness, edema, face edema, lower limb edema, angioneurotic edema, urticaria, hypersensitivity, sweating increased, erythema, chest pain, atrial fibrillation, CHF, MI, increased BP, aggravated HTN, hypotension (including postural hypotension), hyperkalemia, syncope, dyspepsia, diarrhea, pain, UTI, erectile dysfunction, back pain, abdominal pain, muscle cramps (including leg cramps), myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, abnormal hepatic function/liver disorder, renal impairment including acute renal failure, anemia, increased CPK, anaphylactic reaction, tendon pain (including tendonitis, tenosynovitis), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash & urticaria), hypoglycemia (in diabetic patients), angioedema (w/ fatal outcome).

Do not co-administer w/ aliskiren in patients w/ diabetes or renal impairment (GFR <60 mL/min). May increase digoxin peak plasma conc & trough conc. Increase serum conc of lithium. May result in deterioration of renal function including possible acute renal failure w/ NSAIDs. Antihypertensive effects may be attenuated by NSAIDs including COX2 inhibitors. Possible additive pharmacodynamic effects w/ ramipril & ramiprilat.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx